Where the index came from
The homeostasis model assessment was published in 1985. Its purpose was to estimate two things — insulin sensitivity and beta-cell function — from a single pair of fasting measurements, in place of the elaborate clamp studies that were the reference method and were never going to be practical outside a research unit. It was, from the beginning, a convenience: a way to get a defensible approximation from a blood sample anyone could give.
That origin explains both its usefulness and its ceiling. It was designed to describe populations and to track change, and it does that job well. It was not designed to sort individuals into categories, and the literature has never given it a threshold that does so reliably across different groups.
Sources: [1]
The calculation, and why we are not putting a calculator on this page
The index is fasting insulin multiplied by fasting glucose, divided by a constant — the constant differing depending on whether glucose is expressed in mg/dL or mmol/L, which is itself a common source of a wrong answer, since Indian reports use mg/dL and much of the material online assumes mmol/L.
We have deliberately not built a box on this page that takes your two numbers and returns a figure. A number produced without the assay, the laboratory's reference interval, the rest of the panel and the person's history attached to it is not information; it is an invitation to conclude something. This site has one calculator, at /check, it is explicitly non-diagnostic, and it refuses to categorise anybody. Adding a second one that hands out a metabolic score would contradict the reason the first one behaves that way.
There is no universal cut-off, and the authors said so
The clearest statement of the index's limits came from the people who built it. Insulin assays differ between manufacturers and are not fully standardised, so the same blood in two laboratories can yield meaningfully different insulin values and therefore different index values. Reference populations differ. And the relationship the model assumes holds less well at the extremes — in people with substantially reduced beta-cell function, the estimate becomes unreliable in a way the number itself does not disclose.
The practical consequence is simple and widely ignored: a threshold quoted on a website, derived from one population using one assay, is not automatically the threshold for your report. Where a cut-off is used clinically it is used as a prompt to look harder, not as a line that has been crossed.
Sources: [2]
Different Indian studies have proposed different cut-offs for Indian populations, and they do not agree with each other. That disagreement is real, and a page that quotes one of them as settled is misrepresenting the field.
What it is genuinely good at
Two things. First, describing groups: it is why large studies can say something meaningful about insulin sensitivity across thousands of participants without clamping any of them. Second, tracking one person over time, in the same laboratory, with the same assay — where the comparison is against their own previous value rather than against a published line, most of the objections above fall away.
That second use is the one worth remembering if a metabolic panel is repeated at intervals. The direction of travel across two or three measurements in the same laboratory carries more information than any single value does, and it is information a report printed once and filed away can never give.
What a clinician does with it
Treats it as one input. A raised index alongside a normal HbA1c, a raised waist measurement and an abnormal lipid pattern tells a coherent story about compensation, and the compensation is well documented: insulin output rises as sensitivity falls, which is precisely the state the index is designed to detect. The same index value in isolation, with everything else unremarkable, prompts a repeat rather than a conclusion.
The other thing a clinician does is look for the reasons a value might be misleading. Acute illness, a poor fast, a sample that sat too long, and certain medicines all move insulin. A single surprising result is a reason to test again before it is a reason to act.
If your report already has one printed on it
Some Indian laboratories now calculate it automatically and print it with a reference range. That is convenient and it is also where the over-reading usually starts, because a printed range looks authoritative in a way the underlying evidence does not support. It is worth knowing that the range beside it belongs to that laboratory and that assay.
The useful move is not to search the figure and find a page that tells you which category it falls into. It is to take the whole report — glucose, insulin, HbA1c, lipids, liver, thyroid — to somebody who can read them against each other and against your history, and who is registered to be accountable for what they conclude.
Sources: [2]